Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomes.
amyotrophic lateral sclerosis
biomarker
cellular therapy
Journal
Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146
Informations de publication
Date de publication:
09 Apr 2024
09 Apr 2024
Historique:
revised:
16
03
2024
received:
01
09
2023
accepted:
19
03
2024
medline:
10
4
2024
pubmed:
10
4
2024
entrez:
9
4
2024
Statut:
aheadofprint
Résumé
Biomarkers have shown promise in amyotrophic lateral sclerosis (ALS) research, but the quest for reliable biomarkers remains active. This study evaluates the effect of debamestrocel on cerebrospinal fluid (CSF) biomarkers, an exploratory endpoint. A total of 196 participants randomly received debamestrocel or placebo. Seven CSF samples were to be collected from all participants. Forty-five biomarkers were analyzed in the overall study and by two subgroups characterized by the ALS Functional Rating Scale-Revised (ALSFRS-R). A prespecified model was employed to predict clinical outcomes leveraging biomarkers and disease characteristics. Causal inference was used to analyze relationships between neurofilament light chain (NfL) and ALSFRS-R. We observed significant changes with debamestrocel in 64% of the biomarkers studied, spanning pathways implicated in ALS pathology (63% neuroinflammation, 50% neurodegeneration, and 89% neuroprotection). Biomarker changes with debamestrocel show biological activity in trial participants, including those with advanced ALS. CSF biomarkers were predictive of clinical outcomes in debamestrocel-treated participants (baseline NfL, baseline latency-associated peptide/transforming growth factor beta1 [LAP/TGFβ1], change galectin-1, all p < .01), with baseline NfL and LAP/TGFβ1 remaining (p < .05) when disease characteristics (p < .005) were incorporated. Change from baseline to the last measurement showed debamestrocel-driven reductions in NfL were associated with less decline in ALSFRS-R. Debamestrocel significantly reduced NfL from baseline compared with placebo (11% vs. 1.6%, p = .037). Following debamestrocel treatment, many biomarkers showed increases (anti-inflammatory/neuroprotective) or decreases (inflammatory/neurodegenerative) suggesting a possible treatment effect. Neuroinflammatory and neuroprotective biomarkers were predictive of clinical response, suggesting a potential multimodal mechanism of action. These results offer preliminary insights that need to be confirmed.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : California Institute for Regenerative Medicine
Organisme : I AM ALS
Organisme : ALS Association
Informations de copyright
Muscle & Nerve© 2024 The Authors. Muscle & Nerve published by Wiley Periodicals LLC.
Références
Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol. 2017;8:1005.
Zhang W, Xiao D, Mao Q, Xia H. Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther. 2023;8:267. doi:10.1038/s41392‐023‐01486‐5
van Rheenen W, van der Spek RAA, Bakker MK, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron‐specific biology. Nat Genet. 2021;53:1636‐1648. Epub 2021 Dec 6. Erratum in: Nat Genet 2022;54:361. doi:10.1038/s41588‐022‐01020‐3
Diekstra FP, van Vught PWJ, van Rheenen W, et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33(630):e3‐e8. doi:10.1016/j.neurobiolaging.2011.10.029
van Eijk RPA, Jones AR, Sproviero W, et al. Meta‐analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology. 2017;89:1915‐1922. Epub 2017 Oct 4. Erratum in: Neurology 2017;89:2303. doi:10.1212/WNL.0000000000004727
Gao L, Zhou S, Cai H, Gong Z, Zang D. VEGF levels in CSF and serum in mild ALS patients. J Neurol Sci. 2014;346:216‐220.
Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P. Role and therapeutic potential of VEGF in the nervous system. Physiol Rev. 2009;89:607‐648.
Ramírez Hernández E, Sánchez‐Maldonado C, Mayoral Chávez MA, et al. The therapeutic potential of galectin‐1 and galectin‐3 in the treatment of neurodegenerative diseases. Expert Rev Neurother. 2020;20:439‐448.
Xu Z, Henderson RD, David M, McCombe PA. Neurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta‐analysis. PLoS One. 2016;11:e0164625. eCollection 2016. doi:10.1371/journal.pone.0164625
Gille B, De Schaepdryver M, Dedeene L, et al. Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry. 2019;90:1338‐1346.
Galbiati M, Crippa V, Rusmini P, et al. Multiple roles of transforming growth factor beta in amyotrophic lateral sclerosis. Int J Mol Sci. 2020;21:4291.
Iłzecka J, Stelmasiak Z, Dobosz B. Transforming growth factor‐beta 1 (tgf‐Beta 1) in patients with amyotrophic lateral sclerosis. Cytokine. 2002;20:239‐243.
von Neuhoff N, Oumeraci T, Wolf T, et al. Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic. PLoS One. 2012;7:e44401. doi:10.1371/journal.pone.0044401
Vijayakumar UG, Milla V, Cynthia Stafford MY, Bjourson AJ, Duddy W, Duguez SMR. A systematic review of suggested molecular strata, biomarkers and their tissue sources in ALS. Front Neurol. 2019;10:400.
Vu LT, Bowser R. Fluid‐based biomarkers for amyotrophic lateral sclerosis. Neurotherapeutics. 2017;14:119‐134.
Huang F, Zhu Y, Hsiao‐Nakamoto J, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7:1103‐1116.
Thompson AG, Gray E, Verber N, et al. Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. Brain Commun. 2022;4(1):fcac029.
Gaiani A, Martinelli I, Bello L, et al. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: Neurofilament light chain levels in definite subtypes of disease. JAMA Neurol. 2017;74(5):525‐532.
Meyer T, Schumann P, Weydt P, et al. Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in SOD‐1 related ALS: treatment experience in clinical practice. Muscle Nerve. 2023;67:515‐521. doi:10.1002/mus.27818
U.S. Food & Drug Administration. FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene. April 25, 2023. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene
Song N, Scholtemeijer M, Shah K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends Pharmacol Sci. 2020;41:653‐664. Epub 2020 Jul 22. doi:10.1016/j.tips.2020.06.009
Savitz SI, Cox CS Jr. Cell‐based therapies for neurological disorders—the bioreactor hypothesis. Nat Rev Neurol. 2023;19:9‐18.
Ciervo Y, Gatto N, Allen C, et al. Adipose‐derived stem cells protect motor neurons and reduce glial activation in both in vitro and in vivo models of ALS. Mol Ther Methods Clin Dev. 2021;21:413‐433.
Berry JD, Cudkowicz ME, Windebank AJ, et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS: safety, clinical, and biomarker results. Neurology. 2019;93:e2294‐e2305.
Cudkowicz ME, Lindborg SR, Goyal NA, et al. A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle Nerve. 2022;65:291‐302. Epub 2022 Jan 5. Erratum in: Muscle Nerve 2022;66:E26‐E27. doi:10.1002/mus.27697
Van Es MA, Veldink JH, Saris CGJ, et al. Genome‐wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;41:1083‐1087.
Reddy‐Alla S, Bohme MA, Reynolds E, et al. Stable positioning of Unc13 restricts synaptic vesicle fusion to defined release sites to promote synchronous neurotransmission. Neuron. 2017;95:1350‐1364.
Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. Springer; 2000.
Molenberghs G, Thijs H, Jansen I, et al. Analyzing incomplete longitudinal clinical trial data. Biostatistics. 2004;5(3):445‐464.
Muggeo VMR, Adelfio G. Efficient change point detection for genomic sequences of continuous measurements. Bioinformatics. 2011;27:161‐166.
Torbicki A, Bacchi M, Delcroix M, et al. Integrating data from randomized controlled trials and observational studies to assess survival in rare disease. Circ Cardiovasc Qual Outcomes. 2019;12:e005095.
Richardson PG, Jagannath S, Chari A, et al. Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma. eJHaem. 2020;2:48‐55.
Tofersen. U.S. Food & Drug Administration Briefing Book. Mar 22, 2023. https://www.fda.gov/media/166326/download
Najar M, Bouhtit F, Melki R, et al. Mesenchymal stromal cell‐based therapy: new perspectives and challenges. J Clin Med. 2019;8(5):626. doi:10.3390/jcm8050626
Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387:1099‐1110. doi:10.1056/NEJMoa2204705
Gille B, De Schaepdryver M, Gossens J, et al. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 2019;45(3):291‐304.
Brodovitch A, Boucraut J, Delmont E, et al. Combination of serum and CSF neurofilament‐light and neuroinflammatory biomarkers to evaluate ALS. Sci Rep. 2021;11(1):703.
De Schaepdryver M, Lunetta C, Tarlarini C, et al. Neurofilament light chain and C reactive protein explored as predictors of survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2020;91(4):436‐437.
Badyra B, Sułkowski M, Milczarek O, Majka M. Mesenchymal stem cells as a multimodal treatment for nervous system diseases. Stem Cells Transl Med. 2020;9:1174‐1189.
Tan HHG, Westeneng H‐J, van der Burgh HK, et al. The distinct traits of the UNC13A polymorphism in amyotrophic lateral sclerosis. Ann Neurol. 2020;88:796‐806.